FDA looks at obesity devices for children
This article was originally published in Clinica
The FDA's paediatric advisory committee, long focused on drug matters, turns to a timely device topic next month - paediatric obesity, clinical trial designs for devices intended to treat obesity in children and related ethical issues. With as many as 15% of children and adolescents (aged 6-19) obese or overweight, and obesity in adolescents rapidly becoming a national epidemic, manufacturers are interested in devices that can treat the problem.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.